IIM
VERV

INTECH Investment Management’s Verve Therapeutics VERV Stock Holding History

INTECH Investment Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-41,999
Closed -$472K – 2526
2025
Q2 		$472K Sell
41,999
-11,024
-21% -$62.8K ﹤0.01% 1638
2025
Q1 		$242K Buy
53,023
+27,134
+105% +$182K ﹤0.01% 1993
2024
Q4 		$146K Sell
25,889
-8,277
-24% -$46.7K ﹤0.01% 2122
2024
Q3 		$165K Buy
+34,166
New +$198K ﹤0.01% 1779

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

INTECH Investment Management's VERV Position: Q3 2025 in Review

INTECH Investment Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 41,999 shares — an estimated $472K sold.

INTECH Investment Management first reported a position in VERV in Q3 2024 and held it in 4 quarters. The position peaked at $472K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • INTECH Investment Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • INTECH Investment Management sold 41,999 Verve Therapeutics shares in Q3 2025, an estimated $472K.
  • INTECH Investment Management first reported a position in Verve Therapeutics in Q3 2024 and held it in 4 quarters.
  • INTECH Investment Management's Verve Therapeutics position peaked at $472K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on INTECH Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.